clinical trial · NCT07623057
A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
Healthy VolunteerFB102 Single doseFB102 Multiple dosesFB102 Placebo
brief summary
The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.
started
Jun 23, 2026
primary completion
Feb 1, 2027
completion
Feb 1, 2027
last updated
Aug 19, 2026
detailed description
FB-102 will be administered as either a single dose (Part A) or multiple doses (Part B), compared with a placebo control.
Part A (single ascending dose, SAD), participants will receive single dose FB102 will be administered as a single dose.
Part B (multiple ascending dose, MAD), participants will receive multiple doses of FB-102 or placebo.
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity After Single and Multiple Dose Administration of FB102 Administered in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol